Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426978 | 1.00 | GCK (0.81) | GCKKCNH2 | |
| SCHEMBL12430926 | 0.92 | GCK (0.68) | GCKKCNH2 | |
| SCHEMBL1427266 | 0.90 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL2654927 | 0.90 | GCK (0.65) | GCKKCNH2 | |
| SCHEMBL12430928 | 0.89 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL1427001 | 0.88 | GCK (0.97) | GCKKCNH2 | |
| SCHEMBL1426864 | 0.88 | GCK (0.85) | GCKKCNH2 | |
| SCHEMBL1427319 | 0.88 | GCK (0.63) | GCKKCNH2 | |
| SCHEMBL2655992 | 0.88 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL4420471 | 0.88 | GCK (0.80) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885KCNH2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.